These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26100990)

  • 41. Vasovagal reactions in whole blood and apheresis donors: a cross-sectional study on donor haemovigilance data from 2016 to 2019 in Italy.
    Piccinini V; Marano G; Catalano L; Pati I; Veropalumbo E; de Waure C; Pupella S; De Angelis V
    Blood Transfus; 2022 Jul; 20(4):281-291. PubMed ID: 34694220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic impact of donor platelet count and platelet yield in apheresis products: relevance for emerging issues in platelet transfusion therapy.
    Goodnough LT; Ali S; Despotis G; Dynis M; DiPersio JF
    Vox Sang; 1999; 76(1):43-9. PubMed ID: 9933853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postdonation platelet counts are safe when collecting platelets with the Trima Accel using a postdonation platelet count target of > or =50,000 platelets/microL.
    Alex J; Roberts B; Raife T
    J Clin Apher; 2009; 24(5):215-7. PubMed ID: 19816960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vasovagal reactions in blood donors during or immediately after blood donation.
    Zervou EK; Ziciadis K; Karabini F; Xanthi E; Chrisostomou E; Tzolou A
    Transfus Med; 2005 Oct; 15(5):389-94. PubMed ID: 16202053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. National audit of citrate toxicity in plateletpheresis donors.
    Makar YF; Butler MO; Cockersole GM; Gabra G; Serevitch JM
    Transfus Med; 2002 Jun; 12(3):187-91. PubMed ID: 12071875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feasibility and safety of triple dose platelet collection by apheresis.
    Moog R
    J Clin Apher; 2009; 24(6):238-40. PubMed ID: 19908304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing the performance of a plateletpheresis unit at a tertiary-care academic medical center in Mexico: A 6-year experience.
    Jaime-Pérez JC; Beltrán-López AL; Alvarado-Navarro DM; Espinoza-Mares M; Ancer-Rodríguez J; Gómez-Almaguer D
    J Clin Apher; 2021 Dec; 36(6):808-814. PubMed ID: 34411330
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse events and retention of donors of double red cell units by apheresis.
    Keshelashvili K; O'meara A; Stern M; Jirout Z; Pehlic V; Holbro A; Buser A; Sigle J; Infanti L
    Blood Transfus; 2016 Sep; 14(5):391-9. PubMed ID: 27136442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphocytopenia in donors undergoing regular platelet apheresis with cell separators.
    Robbins G; Petersen CV; Brozović B
    Clin Lab Haematol; 1985; 7(3):225-30. PubMed ID: 4075737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vasovagal reactions in apheresis donors.
    Tomita T; Takayanagi M; Kiwada K; Mieda A; Takahashi C; Hata T
    Transfusion; 2002 Dec; 42(12):1561-6. PubMed ID: 12473135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plateletpheresis-associated lymphopenia in frequent platelet donors.
    Gansner JM; Rahmani M; Jonsson AH; Fortin BM; Brimah I; Ellis M; Smeland-Wagman R; Li ZJ; Schenkel JM; Brenner MB; Yefidoff-Freedman R; Sloan SR; Berliner N; Issa NC; Baden LR; Longo DL; Wesemann DR; Neuberg D; Rao DA; Kaufman RM
    Blood; 2019 Feb; 133(6):605-614. PubMed ID: 30429159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of plateletpheresis by donors with low-normal platelet counts.
    Rogers RL; Johnson H; Ludwig G; Winegarden D; Randels MJ; Strauss RG
    J Clin Apher; 1995; 10(4):194-7. PubMed ID: 8770712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current status of leukocyte and platelet administration in cancer therapy.
    Walker EM; Cannon A; Mitchum EN
    Ann Clin Lab Sci; 1983; 13(6):453-73. PubMed ID: 6197928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of immediate vasovagal reaction in blood donors visiting two blood banks of Karachi.
    Rohra DK; Juriasinghani V; Rai K; Azam SI
    Transfus Med; 2010 Jun; 20(3):129-33. PubMed ID: 19958470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recovery of Platelet Count among Apheresis Platelet Donors.
    Thokala RP; Radhakrishnan K; Anandan A; Panicker VK
    J Clin Diagn Res; 2016 Dec; 10(12):EC01-EC04. PubMed ID: 28208861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk factors for acute, moderate to severe donor reactions associated with multicomponent apheresis collections.
    Yuan S; Gornbein J; Smeltzer B; Ziman AF; Lu Q; Goldfinger D
    Transfusion; 2008 Jun; 48(6):1213-9. PubMed ID: 18346014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study.
    Zhao J; Gabriel E; Norda R; Höglund P; Baden L; Diedrich BA; Marits P; Enoksson SL; Gansner JM; Kaufman R; Dickman PW; Edgren G
    Transfusion; 2021 Feb; 61(2):464-473. PubMed ID: 33186486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
    Lozano ML; Rivera J; Vicente V
    Med Clin (Barc); 2012 May; 138(12):528-33. PubMed ID: 21807386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of plateletpheresis on blood coagulation parameters in healthy donors at National Blood Centre, Kuala Lumpur, Malaysia.
    Siti Nadiah AK; Nor Asiah M; Nur Syimah AT; Normi M; Anza E; Aini AN; Mohd Zahari TH; Shahnaz M; Faraizah AK; Faisal MA
    Transfus Apher Sci; 2013 Dec; 49(3):507-10. PubMed ID: 24055412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.